A Phase 1 interventional study of ABBV-990 and Placebo for ABBV-990 in Healthy Volunteers, sponsored by AbbVie. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-27.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
This study will assess how safe ABBV-990 is and how ABBV-990 moves through the body of adult healthy participants. Adverse Events will be assessed.
ABBV-990 is an investigational drug being developed for the treatment of SARS-CoV-2 infections. Participants are randomly assigned to one of the 5 treatment groups. Each group receives different treatment. There is 1 in 4 chance that participants are assigned to placebo. Approximately 40 adult healthy volunteers will be enrolled in a single site in the United States.
Participants will receive oral tablet of ABBV-990 or matching placebo on Day 1 and followed for approximately 30 days.
Participants will be confined for 5 days. Adverse Events and blood tests will be performed.
7,775 studies on the registry are indexed under COVID-19; 482 are open to participants now.
This study's enrollment of 24 is below the median of 100 across 4,175 interventional studies indexed under COVID-19.
Browse COVID-19 studies →AbbVie is the lead sponsor of 969 studies on the registry; 134 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 214 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive ABBV-990 Dose A or matching placebo.
Drug: ABBV-990 · Drug: Placebo for ABBV-990
Participants will receive ABBV-990 Dose B or matching placebo.
Drug: ABBV-990 · Drug: Placebo for ABBV-990
Participants will receive ABBV-990 Dose C or matching placebo.
Drug: ABBV-990 · Drug: Placebo for ABBV-990
Participants will receive ABBV-990 Dose D or matching placebo.
Drug: ABBV-990 · Drug: Placebo for ABBV-990
Participants will receive ABBV-990 Dose E or matching placebo.
Drug: ABBV-990 · Drug: Placebo for ABBV-990
Oral Tablet
Oral Tablet
Number of Participants Experiencing Adverse Events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
Time frame: Up to approximately 30 days
Maximum Observed Plasma Concentration (Cmax) of ABBV-990
Cmax of ABBV-990.
Time frame: Up to approximately 5 days
Time to Cmax (Tmax) of ABBV-990
Tmax of ABBV-990.
Time frame: Up to approximately 5 days
Apparent Terminal Phase Elimination Rate Constant (β) of ABBV-990
Apparent terminal phase elimination rate constant of ABBV-990.
Time frame: Up to approximately 5 days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-990
Terminal phase elimination half-life of ABBV-990.
Time frame: Up to approximately 5 days
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-990
AUCt of ABBV-990.
Time frame: Up to approximately 5 days
AUC From Time 0 to Infinite Time (AUCinf) of ABBV-990
AUCinf of ABBV-990.
Time frame: Up to approximately 5 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2022 to primary completion in Sep 2022, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.